Market Intelligence, Clinical Progress, and High-Purity Reagents for CNS and Cardiovascular Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ADRA2C drug discovery. All products are sequence verified, high purity (>95%), endotoxin controlled (<1 EU/μg), and HEK293 expressed where applicable to preserve native glycosylation.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Membrane Protein | ADRA2C Full-Length Membrane Protein or N-Terminal ECD; detergent solubilized or membrane extracts for SPR/radioligand binding; >95% purity, endotoxin <1 EU/μg. | View ADRA2C Products |
| Gene Delivery | ADRA2C Premade Lentivirus Particles; full-length ORF (NM_000683), CMV promoter, puromycin resistance; optimized for stable cell line generation preserving native GPCR conformation. | View ADRA2C Products |
| Benchmark Antibody | Anti-ADRA2C Recombinant Monoclonal Antibody (neutralizing); sequence verified, endotoxin controlled, suitable as positive control. | View ADRA2C Products |
| Validator / siRNA | ADRA2C siRNA Set (3 unique sequences) for knockdown verification in functional assays (cAMP, calcium flux) and false-positive exclusion. | View ADRA2C Products |
| Related Target A | ADRA2A (Alpha-2A Adrenergic Receptor); critical counter-screen to avoid sedation/cardiovascular off-targets. | View ADRA2A Products |
| Related Target B | ADRA2B (Alpha-2B Adrenergic Receptor); vascular-specific subtype required for selectivity profiling. | View ADRA2B Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subtype selectivity (vs ADRA2A/2B) | Complete ADRA2 sub-type panel with human/mouse/cyno ortholog proteins; sequence verified by mass spec; enables precise radioligand/SPR displacement counter-screening. |
| Native GPCR conformation maintenance | Lentivirus-based stable HEK293/CHO cell lines; preserves 7-TM membrane context for accurate binding, cAMP, and β-arrestin functional assays. |
| Cross-species translation (human/mouse/cyno) | Species-specific ORF lentivirus and membrane preparations; >95% purity, endotoxin controlled; preclinical bridging for efficacy and safety. |
| Assay window variability and false positives | Endotoxin <1 EU/μg; validated siRNA included for target-specific knockdown controls; robust cAMP/calcium flux readouts. |
| Blood-brain barrier penetration assessment | Small-molecule-focused tools; receptor occupancy assays using high-affinity membrane preparations. |
Live ADRA2C R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ADRA2C-selective therapeutics is intensifying. Early efforts focused on non-selective alpha-2 modulators, but the current development bottleneck is achieving strict receptor subtype selectivity to avoid ADRA2A-mediated cardiovascular and sedative side effects. Leading players like Orion Pharma (ORM-12741, Phase 2 Alzheimer's) are advancing small-molecule antagonists that spare ADRA2A. Meanwhile, emerging modalities include biased agonists for pain modulation and targeted protein degradation for refractory CNS disorders. The next wave of R&D demands robust, high-fidelity cell-based functional assays to support structure-based drug design and combination therapies (e.g., with NMDA modulators or BDNF pathway activators). Critical unmet needs remain: cross-species preclinical tools and blood-brain barrier penetration assessment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Antagonist) | Orion Pharma, Janssen, Eli Lilly | Alzheimer's agitation, schizophrenia, cognitive impairment | Subtype selectivity panel (need ADRA2A/2B/2C proteins & cell lines for radioligand/cAMP assays) |
| Small Molecule (Agonist) | Academic / Biotech consortia | Pain (neuropathic), Raynaud's phenomenon | Functional screening (cAMP/β-arrestin assays with native GPCR cells) |
| Biologics / Peptides | Emerging CNS biotechs | Refractory CNS disorders | Epitope mapping (ECD fragments, sequence-verified targets) |
| Radioligand Diagnostics | Academic consortia | Receptor occupancy (CNS) | High-affinity membrane preparations (sequence verified) |
| Targeted Protein Degradation | Emerging biotech | Refractory pain | Cell-based internalization assay (lentivirus stable lines) |